<DOC>
	<DOCNO>NCT02032888</DOCNO>
	<brief_summary>A study efficacy safety combination daclatasvir sofosbuvir treatment hepatitis C virus HIV coinfection .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Combination Therapy With Daclatasvir Sofosbuvir Treatment HIV Hepatitis C Virus Coinfection .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Patients must able understand agree to/comply prescribe dose regimen procedure , report regularly schedule study visit , reliably communicate study personnel adverse event concomitant medication Patients chronically infected hepatitis C virus ( HCV ) genotype 1 , 2 , 3 , 4 , 5 , 6 , document positive HCV RNA screen Patients HCV treatmentnaive Patients HCV treatmentexperienced prior antiHCV therapy discontinue complete least 12 week prior screen Patients HCV RNA â‰¥10,000 IU/mL screen Patients HIV1 infection Key Presence AIDsdefining opportunistic infection , define Centers Disease Control Prevention , within 12 week prior study entry Patients infect HIV2 Liver organ transplant ( include hematopoietic stem cell transplant ) cornea hair Current known history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior screen Documented suspect hepatocellular carcinoma , evidence previously obtain image study liver biopsy ( screen image study/liver biopsy perform Evidence decompensated liver disease , include radiologic criterion , history presence ascites , bleed varix , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>